Pharmacokinetics and bioavailability of Naprosyn CR 500 mg tablet, a new controlled-release formulation of naproxen, after single and multiple dosing

Wanwimolruk, Sompon; Lipschitz, Stanley; Roberts, Michael S.

doi:10.1016/0378-5173(91)90250-r

Cited by 4 publications

(2 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, toxicity often occurs at SA concentrations about 300 g ml −1 [33]. On the other hand, mean values of maximum plasma NX concentration under therapeutic doses are between 40 and 65 g ml −1 , depending on the treatment days [34]. Overdoses of NX produce plasma concentrations larger than 200 g ml −1 [1].…”

Section: Serum Samplesmentioning

confidence: 99%

Combined liquid and solid-surface room temperature fluorimetric determination of naproxen and salicylate in serum

Ibáñez

Escandar

2005

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

Section: Serum Samplesmentioning

confidence: 99%

Combined liquid and solid-surface room temperature fluorimetric determination of naproxen and salicylate in serum

Ibáñez

Escandar

2005

Journal of Pharmaceutical and Biomedical Analysis

View full text Add to dashboard Cite

“…Na Figura 64 são apresentados os espectros de FT-IR obtidos para o fármaco puro e para as formulações NPVA, NDSP, NPEG, NSER e NALG, tendo sido empregada a mesma escala para todos os perfis, evidenciando as diferenças de intensidades da banda em cada formulação. ARCO et al, 2004;WEI et al, 2004).…”

Section: Grupos Funcionaisunclassified

Desenvolvimento de partículas a partir da blenda de sericina e alginato para incorporação e liberação modificada de anti-inflamatórios cetoprofeno e naproxeno

Dantas de Freitas

View full text Add to dashboard Cite

show abstract

Single‐ and Multiple‐Dose Pharmacokinetic Comparison of a Sustained‐Release Tablet and Conventional Tablets of Naproxen in Healthy Volunteers

Zhou¹,

Zhang²,

Lu³

et al. 1998

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The pharmacokinetics of a new sustained-release tablet of naproxen (500 mg once daily) were compared with a conventional tablet (250 mg twice daily) after single- or multiple-dose oral administration in healthy volunteers using an open, randomized two-way crossover experimental design. Naproxen was well absorbed from the sustained-release tablet (approximately 97%) compared with the conventional tablet. Pharmacokinetic data showed that the sustained-release formulation reached significantly delayed mean peak plasma levels (Cmax) in both single- and multiple-dose studies and lower Cmax in a single-dose study than the conventional formulation. However, there were no statistically significant differences in other pharmacokinetic parameters, including area under the concentration-time curve (AUC), elimination half-life (t1/2), and elimination rate constant (Ke), in either single- or multiple-dose studies between the two treatments. In addition, there were no significant differences between formulations in Cmax, minimum plasma concentration (Cmin), and fluctuation index in the multiple-dose study.

show abstract

Pharmacokinetics and bioavailability of Naprosyn CR 500 mg tablet, a new controlled-release formulation of naproxen, after single and multiple dosing

Cited by 4 publications

References 7 publications

Combined liquid and solid-surface room temperature fluorimetric determination of naproxen and salicylate in serum

Combined liquid and solid-surface room temperature fluorimetric determination of naproxen and salicylate in serum

Desenvolvimento de partículas a partir da blenda de sericina e alginato para incorporação e liberação modificada de anti-inflamatórios cetoprofeno e naproxeno

Single‐ and Multiple‐Dose Pharmacokinetic Comparison of a Sustained‐Release Tablet and Conventional Tablets of Naproxen in Healthy Volunteers

Contact Info

Product

Resources

About